IRIS
FURFARO, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.568
NA - Nord America 1.382
EU - Europa 992
SA - Sud America 704
AF - Africa 70
OC - Oceania 4
Totale 5.720
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.275
SG - Singapore 1.021
CN - Cina 615
BR - Brasile 591
HK - Hong Kong 480
IT - Italia 337
VN - Vietnam 220
DE - Germania 130
SE - Svezia 123
GB - Regno Unito 82
RU - Federazione Russa 65
FI - Finlandia 56
CA - Canada 51
AR - Argentina 48
MX - Messico 43
IN - India 42
PL - Polonia 41
NL - Olanda 39
BD - Bangladesh 31
JP - Giappone 31
AT - Austria 28
ID - Indonesia 26
EG - Egitto 25
EC - Ecuador 24
IQ - Iraq 23
ZA - Sudafrica 23
FR - Francia 21
ES - Italia 19
TR - Turchia 16
CO - Colombia 14
UA - Ucraina 11
LU - Lussemburgo 8
PT - Portogallo 8
PY - Paraguay 8
UZ - Uzbekistan 8
CL - Cile 7
MA - Marocco 6
MY - Malesia 6
PK - Pakistan 6
AZ - Azerbaigian 5
SA - Arabia Saudita 5
IL - Israele 4
JO - Giordania 4
PE - Perù 4
TW - Taiwan 4
AU - Australia 3
BE - Belgio 3
ET - Etiopia 3
KY - Cayman, isole 3
LB - Libano 3
LT - Lituania 3
NP - Nepal 3
RS - Serbia 3
SN - Senegal 3
TN - Tunisia 3
UY - Uruguay 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
GY - Guiana 2
IE - Irlanda 2
IR - Iran 2
KE - Kenya 2
KW - Kuwait 2
KZ - Kazakistan 2
PA - Panama 2
RO - Romania 2
SY - Repubblica araba siriana 2
TG - Togo 2
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
CU - Cuba 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GR - Grecia 1
HN - Honduras 1
KH - Cambogia 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
TZ - Tanzania 1
Totale 5.720
Salva come PNG Salva come JPEG
Città #
Singapore 480
Hong Kong 473
Dallas 275
Ashburn 229
Hefei 177
Beijing 143
Ho Chi Minh City 89
New York 76
Milan 75
Los Angeles 67
Munich 67
Shanghai 62
Lawrence 58
Princeton 58
São Paulo 48
Hanoi 47
Helsinki 35
Moscow 32
Warsaw 32
Montreal 21
Poplar 20
Brooklyn 19
Denver 19
London 18
Mexico City 18
Rome 18
Stockholm 18
Tokyo 18
Chennai 17
Johannesburg 17
Chicago 16
Manchester 16
Phoenix 16
Nuremberg 15
Frankfurt am Main 14
Rio de Janeiro 14
Santa Clara 14
Vienna 14
Baghdad 13
Council Bluffs 13
Orem 13
Turku 13
Curitiba 12
Belo Horizonte 11
Brasília 11
Toronto 11
Campinas 10
Charlotte 10
Porto Alegre 10
Ankara 9
Atlanta 9
Boston 9
Naples 9
Quito 9
Slough 9
Amsterdam 8
Boardman 8
Da Nang 8
Esch-sur-Alzette 8
Falkenstein 8
Florence 8
Seattle 8
Tashkent 8
Brescia 7
Guayaquil 7
Ninh Bình 7
Querétaro 7
Salvador 7
Sorocaba 7
Wuhan 7
Dhaka 6
Haiphong 6
Houston 6
Hyderabad 6
Mumbai 6
Niigata 6
Padova 6
Ribeirão Preto 6
Rosetta 6
Washington 6
Baku 5
Bari 5
Biên Hòa 5
Bologna 5
Cairo 5
Erbil 5
Guarulhos 5
Hải Dương 5
Istanbul 5
Las Vegas 5
Messina 5
Nova Iguaçu 5
Piracicaba 5
Praia Grande 5
Riyadh 5
Saint Louis 5
Shenzhen 5
Thái Bình 5
Turin 5
Amman 4
Totale 3.298
Salva come PNG Salva come JPEG
Nome #
Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study 149
Fecal, Blood, and Urinary Biomarkers in Inflammatory Bowel Diseases 108
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 88
Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches 73
Endoscopic Treatment Approaches for Inflammatory Bowel Diseases: Old Friends and New Weapons 68
P139 The learning curve of intestinal ultrasonography in assessing inflammatory bowel disease : preliminary results 67
Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial 65
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study 64
Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment 63
Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment 62
Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study 59
Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease 59
Advancing Colorectal Cancer Prevention in Inflammatory Bowel Disease (IBD): Challenges and Innovations in Endoscopic Surveillance 58
Targeting mucosal healing in Crohn’s disease: efficacy of novel pathways and therapeutic targets 56
Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience 56
Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's disease 55
A Comprehensive Multidisciplinary Approach to Diagnosing Chronic Inflammatory Bowel Diseases: Integration of Clinical, Endoscopic, and Imaging Modalities 55
Multiple Ileal and Colonic Stenoses: Is It Always Crohn’s Disease? 51
Risk factors for depression and anxiety in Crohn's disease 50
New Technologies in Digestive Endoscopy for Ulcerative Colitis Patients 49
Neutrophil-only Histological Assessment of Ulcerative Colitis Correlates with Endoscopic Activity and Predicts Long-Term Outcomes in a Multicentre Study 48
Ulcerative colitis : current pharmacotherapy and future directions 48
y ANTIBODIES TO INFLIXIMAB IN PATIENTS TREATED WITH EITHER THE REFERENCE BIOLOGIC OR THE BIOSIMILAR CT-P13 SHOW IDENTICAL REACTIVITY TOWARDS BIOSIMILARS CT-P13 AND SB2 IN INFLAMMATORY BOWEL DISEASE 48
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD 48
Small Bowel Cancer in Crohn’s Disease 47
Leaving behind the Mucosa: Advances and Future Directions of Intestinal Ultrasound in Ulcerative Colitis 46
Bowel ultrasound in inflammatory bowel disease: How far in the grayscale? 46
Gastrointestinal Ultrasound in Infectious Diseases: A Comprehensive Review 46
Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era 45
Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors 45
Accuracy of Information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO Guidelines 45
Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality? 45
Bowel ultrasound is accurate in assessing disease activity in ulcerative colitis 45
Psychological Functioning of Patients With Inflammatory Bowel Disease 45
Gut Microbiota Metabolites: Unveiling Their Role in Inflammatory Bowel Diseases and Fibrosis 44
STIMULATION OF CYP450-MEDIATED omega-3 DOCOSAHEXAENOIC ACID (DHA) METABOLISM VIA MFSD2A AS A NOVEL THERAPY FOR INFLAMMATORY BOWEL DISEASE 43
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? 43
The Role of IL-23 Inhibitors in Crohn’s Disease 42
Inflammatory Bowel Disease and Colorectal Cancer 42
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease 42
Psychological factors and quality of life in inflammatory bowel diseases patients: the Psycho study 42
An Unusual Case of Cardiac Involvement in Crohn's Disease 42
Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis 41
Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis 41
Biosimilars of adalimumab: the upcoming challenge in IBD 41
Can IL-23 be a good target for ulcerative colitis? 41
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis 41
Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases 40
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 40
SWITCHING FROM INFLIXIMAB ORIGINATOR TO CT-P13 IS NOT RELATED TO INCREASED IMMUNOGENICITY IN IBD PATIENTS: A PROSPECTIVE CASE-CONTROL STUDY 40
Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts 40
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 40
Abdominal pain after minor trauma in a patient with Crohn's disease 39
The Management of Postoperative Recurrence in Crohn’s Disease 38
Risk Factor Analysis for Therapy Related Adverse Events and Infections in Elder Patients With Inflammatory Bowel Disease; An Analysis From the iG-IBD Aged Study 38
Point-of-Care Ultrasound in Inflammatory Bowel Disease 38
Raising the bar in ulcerative colitis management 37
Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future 37
BOWEL ULTRASOUND IS ACCURATE IN ASSESSING DISEASE ACTIVITY IN ULCERATIVE COLITIS 37
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 37
The role of filgotinib in ulcerative colitis and Crohn's disease 36
ASSESSMENT OF THE DISEASE EXTENSION IN CHILDREN AND ADOLESCENTS WITH IBD: COMPARISON OF BOWEL ULTRASOUND AND MAGNETIC RESONANCE ENTEROGRAPHY 36
Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps 36
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study 36
Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block 36
JAK inhibitors: Novel developments in management of ulcerative colitis 36
Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective study 36
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice 36
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology 36
The Role of Fecal Microbiota Transplantation in IBD 35
Improving quality of care in endoscopy of inflammatory bowel disease: can we do better? 35
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease 35
Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease 35
Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment—insights from Phase II and III trials 35
Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures 34
Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISA 34
Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of C-13-urea 34
Prevalence, characteristics, management, and outcomes of difficult-to-treat inflammatory bowel disease 33
Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn's disease: a prospective cohort study 33
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 33
Emerging therapeutic targets and strategies in Crohn's disease 33
Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile 33
Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question 32
Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art 32
Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience 32
The safety of biological pharmacotherapy for the treatment of ulcerative colitis 32
Modulation of sphingosine-1-phosphate in ulcerative colitis 32
Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men 32
Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach 32
Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration 32
Illness perception in IBD patients: a prospective study 31
Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study 31
RAPID DETECTION OF ANTI-INFLIXIMAB ANTIBODIES IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH THE REFERENCE BIOLOGIC OR THE BIOSIMILAR CT-P13: PERFORMANCE COMPARISON WITH ELISA 31
Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners 31
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis 31
Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making 31
Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic 30
COMPARATIVE ACCURACY OF US VERSUS MRI AND COLONOSCOPY IN ASSESSING DISEASE ACTIVITY AND COMPLICATIONS AND INFLUENCING THE DECISION-MAKING PROCESS IN CROHN'S DISEASE 30
JAK inhibitors in crohn's disease: ready to go? 30
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study 29
Totale 4.375
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.916
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.916
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202292 0 0 0 73 1 5 0 1 0 2 5 5
2022/2023252 149 36 9 2 1 25 10 9 8 2 0 1
2023/202461 1 3 2 0 4 16 3 6 0 0 2 24
2024/20251.881 106 8 13 3 1 56 134 295 357 495 147 266
2025/20263.661 663 597 505 1.065 765 66 0 0 0 0 0 0
Totale 5.947